• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular targets of 5FU and combined chemotherapy of 5FU plus low dose CDDP for head and neck cancer

Research Project

Project/Area Number 13671812
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Otorhinolaryngology
Research InstitutionAichi Cancer Center

Principal Investigator

HASEGAWA Yasuhisa  Aichi Cancer Center Research Institute, Research Fellow, 研究所, 研究員 (10261207)

Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2002: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2001: ¥2,100,000 (Direct Cost: ¥2,100,000)
Keywordshead and neck cancer / CDDP / 5FU / in vitro chemosensitivity / real time RT-PCR / mRNA / HER-2 / COX-2 / DPD / OPRT / TS / 抗癌剤感受性
Research Abstract

We examined the factors regulating effectiveness of anti-cancer agents especially, 5FU and CDDP, for the purpose of establishing of order-made cancer chemotherapy that will improve prognosis and QOL.
Materials and methods : 1) For organ preservation, we administered neoadjuvant 5FU and CDDP chemotherapy (FP) to head and neck cancer patients. 2) We conducted in vitro chemosensitivity tests using histoculture drug response assay (HDRA) on surgical specimens, and performed real-time RT-PCR for the quantitative detection of expression levels of mRNA that may regulate anti-cancer agents. We then analyzed the correlation between them.
Results : 1) Among 13 untreated head and neck cancer patients who underwent FP therapy, 10 patients (77%) achieved PR or above. 2) Along with the elevation of HER-2 mRNA expression levels, there was a downward tendency in the inhibition index for 5FU and CDDP in surgical specimens, and we detected a significant upward tendency in HER-2 mRNA expression levels among non-responders of HDRA to 5FU and CDDP.
On the other hand, the 5FU inhibition index rose with elevations in COX-2 mRNA expression levels, although the significance of this is unclear. This should be investigated in the future with a greater number of patients.
Conclusion : There is a need to analyze the enzyme activity and quantitatively detect expression levels of mRNA for factors relating to metabolism of 5FU. Furthermore, detecting the molecular marker that represents the tumor characteristics in individual patients, we hope to establish order-made cancer chemotherapy that will allow us to select the best regimen for patients through clinical trials. We also hope to apply detection and selection cDNA array to the molecular marker.

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] 長谷川泰久: "頭頸部がんの化学・放射線療法"癌と化学療法. 29巻5号. 677-683 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Hasegawa Y: "Ghemo-radiotherapy for head and neck cancer"Jpn J Cancer Chemother. 29. 677-683 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] 長谷川泰久: "頭頸部がんの化学・放射線療法"癌と化学療法. 29巻5号. 677-683 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] 長谷川泰久, 早川和喜: "舌癌の化学療法-in vitro感受性試験から分子標的へ-"耳鼻と臨床. 47巻補冊1号. 1-5 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi